Format

Send to

Choose Destination
Transl Res. 2016 Jan;167(1):183-91. doi: 10.1016/j.trsl.2015.04.015. Epub 2015 May 5.

Therapeutic targeting of acute lung injury and acute respiratory distress syndrome.

Author information

1
Department of Internal Medicine, Pulmonary and Critical Care, University of Michigan Medical School, Ann Arbor, Mich.
2
Department of Pathology, University of Michigan Medical School, Ann Arbor, Mich. Electronic address: pward@umich.edu.

Abstract

There is no Food and Drug Administration-approved treatment for acute respiratory distress syndrome (ARDS), in spite of the relatively large number of patients with the diagnosis. In this report, we provide an overview of preclinical studies and a description of completed and future clinical trials in humans with ARDS. Preclinical studies dealing with acute lung injury have suggested roles for complement and complement receptors, as well as the evolving role of histones, but details of these pathways are inadequately understood. Anti-inflammatory interventions have not been convincingly effective. Various cell growth factors are being considered for clinical study. Interventions to block complement activation or its products are under consideration. Stem cell therapies have shown efficacy in preclinical studies, which have motivated phase I/II trials in humans with ARDS.

PMID:
26003524
PMCID:
PMC4635065
DOI:
10.1016/j.trsl.2015.04.015
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center